• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者对肥胖治疗风险的看法:一项创新的健康倡议——肥胖表型分层以优化未来肥胖治疗(IMI2 SOPHIA)定性研究。

Patient perspectives on the risks of obesity treatment: An innovative health initiative stratification of obesity phenotypes to optimise future obesity therapy (IMI2 SOPHIA) qualitative study.

作者信息

Farrell Emma, Nadglowski Joseph, Hollmann Eva, le Roux Carel W, McGillicuddy Deirdre

机构信息

University College Dublin, Dublin, Ireland.

Obesity Action Coalition, Tampa, FL, USA.

出版信息

Obes Pillars. 2024 Aug 23;12:100129. doi: 10.1016/j.obpill.2024.100129. eCollection 2024 Dec.

DOI:10.1016/j.obpill.2024.100129
PMID:39268014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11389537/
Abstract

BACKGROUND

The uptake of obesity treatments remains disproportionally low in people living with the disease, even with the advent and availability of GLP-1 agonists in recent years. Efforts to understand this discrepancy have centred on literature syntheses and Healthcare Professionals' (HCPs) perspectives on the barriers to obesity treatment. This study focuses on patient perspectives on the of obesity treatment.

METHOD

This qualitative study consisted of online focus groups with 30 adults with obesity from Europe and North America. The focus group discussions were recorded, transcribed verbatim and analysed thematically.

RESULTS

Patients identified three risks associated with obesity treatment: (a) the risk that they can't access treatment; (b) the risk that they would fail to meet treatment expectations - their own, their HCPs and societal expectations, and (c) the risk that the treatment would be 'successful' but that they would lose their sense of self, their coping mechanisms and identity along with weight.

CONCLUSION

Understanding patient concerns about the risks of obesity treatment is essential to addressing obesity treatment inertia.

摘要

背景

尽管近年来胰高血糖素样肽-1(GLP-1)激动剂问世且可获取,但肥胖症患者对肥胖治疗的接受程度仍然极低。为理解这一差异所做的努力主要集中在文献综述以及医疗保健专业人员(HCPs)对肥胖治疗障碍的看法上。本研究聚焦于患者对肥胖治疗的看法。

方法

这项定性研究由与来自欧洲和北美的30名成年肥胖者进行的在线焦点小组组成。焦点小组讨论进行了录音,逐字转录并进行了主题分析。

结果

患者确定了与肥胖治疗相关的三种风险:(a)无法获得治疗的风险;(b)未能达到治疗期望的风险——他们自己的、其医疗保健专业人员的以及社会期望,以及(c)治疗“成功”但他们会随着体重减轻而失去自我意识、应对机制和身份认同的风险。

结论

了解患者对肥胖治疗风险的担忧对于解决肥胖治疗惰性至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4674/11389537/599bf9f196cc/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4674/11389537/599bf9f196cc/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4674/11389537/599bf9f196cc/ga1.jpg

相似文献

1
Patient perspectives on the risks of obesity treatment: An innovative health initiative stratification of obesity phenotypes to optimise future obesity therapy (IMI2 SOPHIA) qualitative study.患者对肥胖治疗风险的看法:一项创新的健康倡议——肥胖表型分层以优化未来肥胖治疗(IMI2 SOPHIA)定性研究。
Obes Pillars. 2024 Aug 23;12:100129. doi: 10.1016/j.obpill.2024.100129. eCollection 2024 Dec.
2
Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists.医疗保健专业人员对肥胖症的认知与管理以及对胰高血糖素、胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽受体激动剂和双重激动剂的了解。
Obes Sci Pract. 2024 May 4;10(3):e756. doi: 10.1002/osp4.756. eCollection 2024 Jun.
3
Healthcare professionals perceptions of obesity management: An IMI2 SOPHIA qualitative study.医疗保健专业人员对肥胖管理的看法:IMI2 SOPHIA 定性研究。
Clin Obes. 2024 Oct;14(5):e12686. doi: 10.1111/cob.12686. Epub 2024 Jun 27.
4
Patient perspectives on personalised medicine for obesity: An IMI2 SOPHIA Study.患者对肥胖个性化医学的看法:IMI2 SOPHIA 研究。
Obes Res Clin Pract. 2024 May-Jun;18(3):216-221. doi: 10.1016/j.orcp.2024.06.004. Epub 2024 Jun 29.
5
Patient perceptions of success in obesity treatment: An IMI2 SOPHIA study.患者对肥胖治疗成功的认知:一项IMI2索菲亚研究。
Obes Sci Pract. 2024 Aug 17;10(4):e70001. doi: 10.1002/osp4.70001. eCollection 2024 Aug.
6
Caregivers' and healthcare professionals' perspective of barriers and facilitators to health service access for asthmatic children: a qualitative study.照顾者和医疗保健专业人员对哮喘儿童获得卫生服务的障碍和促进因素的看法:一项定性研究。
BMJ Open Respir Res. 2021 Dec;8(1). doi: 10.1136/bmjresp-2021-001066.
7
Exploring the ideas of young healthcare professionals from selected countries regarding rural proofing.探索来自选定国家的年轻医疗保健专业人员对农村证明的看法。
Rural Remote Health. 2023 Nov;23(4):8294. doi: 10.22605/RRH8294. Epub 2023 Nov 18.
8
Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy.医疗服务提供者与2型糖尿病患者协作的实用指南:推进治疗与启动注射治疗
Diabetes Ther. 2023 Feb;14(2):425-446. doi: 10.1007/s13300-022-01330-z. Epub 2022 Dec 15.
9
How do people living with obesity who use obesity services perceive healthcare professionals' representation of the disease on social media? An interpretative phenomenological analysis.肥胖患者对社交媒体中医护人员对肥胖症描述的看法如何?一项阐释性现象学分析。
BMJ Open. 2024 Apr 15;14(4):e081066. doi: 10.1136/bmjopen-2023-081066.
10
Qualitative evaluation of the acceptability and feasibility among healthcare professionals and patients of an ART multi-cycle treatment planning and continuation intervention prototype.定性评估医疗保健专业人员和患者对一种 ART 多周期治疗计划和延续干预原型的可接受性和可行性。
Hum Reprod. 2023 Mar 1;38(3):430-443. doi: 10.1093/humrep/deac272.

本文引用的文献

1
Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022.2014 年至 2022 年胰高血糖素样肽-1 受体激动剂使用趋势。
J Am Pharm Assoc (2003). 2024 Jan-Feb;64(1):133-138. doi: 10.1016/j.japh.2023.10.002. Epub 2023 Oct 10.
2
Incidence of self-harm after bariatric surgery: A nationwide registry-based matched cohort study.减重手术后的自伤发生率:一项基于全国登记的匹配队列研究。
Clin Obes. 2023 Jun;13(3):e12576. doi: 10.1111/cob.12576. Epub 2023 Jan 6.
3
At home and at risk: The experiences of Irish adults living with obesity during the COVID-19 pandemic.
身处家中且面临风险:爱尔兰肥胖成年人在新冠疫情期间的经历。
EClinicalMedicine. 2022 Jul 18;51:101568. doi: 10.1016/j.eclinm.2022.101568. eCollection 2022 Sep.
4
The lived experience of patients with obesity: A systematic review and qualitative synthesis.肥胖患者的生活体验:系统评价和定性综合。
Obes Rev. 2021 Dec;22(12):e13334. doi: 10.1111/obr.13334. Epub 2021 Aug 16.
5
Obesity management: at the forefront against disease stigma and therapeutic inertia.肥胖管理:站在对抗疾病污名化和治疗惰性的前沿。
Eat Weight Disord. 2022 Mar;27(2):761-768. doi: 10.1007/s40519-021-01217-1. Epub 2021 May 29.
6
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.持续每周皮下注射司美格鲁肽与安慰剂对超重或肥胖成年人体重维持的影响:STEP 4 随机临床试验。
JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.
7
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
8
Obesity in adults: a clinical practice guideline.成人肥胖:临床实践指南。
CMAJ. 2020 Aug 4;192(31):E875-E891. doi: 10.1503/cmaj.191707.
9
Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015.在 8 家大型医疗保健机构的 220 万成年人中使用抗肥胖药物:2009-2015 年。
Obesity (Silver Spring). 2019 Dec;27(12):1975-1981. doi: 10.1002/oby.22581. Epub 2019 Oct 11.
10
An Examination of Who Is Eligible and Who Is Receiving Bariatric Surgery in England: Secondary Analysis of the Health Survey for England Dataset.谁有资格接受减肥手术以及谁在英国接受减肥手术的调查:对英国健康调查数据集的二次分析。
Obes Surg. 2019 Oct;29(10):3246-3251. doi: 10.1007/s11695-019-03977-3.